Purdue Pharma launches no-profit treatment to reverse opioid overdose effects

Five months after the FDA approved Purdue Pharma’s opioid antagonist injection, nalmefene hydrochloride, the no-profit treatment is now available for use, according to a June 21 press release

Advertisement

Nalmefene hydrochloride is for a “complete or partial reversal of opioid drug effects,” such as respiratory depression, the press release said.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.